Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/306% above fair value

$16.42−0.09 (-0.55%)

Close on Nov 13, 2026Market cap $892.71MP/E –Yield –

Beta Bionics statistics

73 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Feb 16, 2027 (estimated, after the close)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $892.71M; $498.53M
Enterprise Value: $652.50M; $433.11M
PS Ratio: 7.01; 2.94
PB Ratio: 2.22; 3.24
P/TBV Ratio: 2.22; 4.81

Enterprise valuationIndustry

EV / Sales: 5.13; 2.60

Share statisticsIndustry

Shares Outstanding: 54M; 43M
Shares Change (YoY): 44.5%; 3.32%
Shares Change (QoQ): 20.9%; 0.20%
Float: 49M; 37M
Shares Held by Insiders: 9.33%; 10.5%
Shares Held by Institutions: 88.2%; 60.5%

Short sellingIndustry

Short Interest: 5M; –
Short Interest Change: -28.0%; -2.57%
Short % of Float: 10.1%; 5.11%
Short % of Shares Outstanding: 9.16%; 3.98%
Days to Cover: 3.94; 3.94

Stock price statisticsIndustry

52-Week High: $32.71; –
52-Week Low: $8.80; –
20-Day Moving Average: $17.45; –
50-Day Moving Average: $18.47; –
200-Day Moving Average: $14.82; –
Average True Range (14): $1.49; –
Price Change (1 Week): 4.59%; 0.99%
Price Change (1 Month): -5.14%; -3.52%
Price Change (3 Months): -6.49%; -7.86%
Price Change (6 Months): 73.6%; -1.12%
Price Change (YTD): -46.1%; -2.92%
Price Change (1 Year): -41.7%; -1.37%
Average Volume (10 Days): 1M; –
Average Volume (20 Days): 1M; –
Average Volume (90 Days): 1M; –
Relative Volume: 0.88; 0.76
Relative Strength Index (14): 45.5; 46.7
Volatility (1 Year): 84.8%; 64.2%

MarginsIndustry

Gross Margin: 58.6%; 55.9%
Operating Margin: -72.7%; -5.12%
Profit Margin: -65.3%; -9.29%
EBITDA Margin: -72.7%; -2.52%
FCF Margin: -51.8%; 0.65%

Returns on capitalIndustry

Return on Equity (ROE): -23.9%; -17.3%
Return on Assets (ROA): -21.5%; -12.3%
Return on Invested Capital (ROIC): -64.4%; -2.83%
Return on Capital Employed (ROCE): -22.5%; -8.13%

Financial positionIndustry

Current Ratio: 8.92; 2.49
Quick Ratio: 7.94; 1.53

GrowthIndustry

Revenue Growth (YoY): 43.7%; 9.42%

EfficiencyIndustry

Asset Turnover: 0.33; 0.59
Inventory Turnover: 2.43; 2.20
Revenue Per Employee: $303.01K; $331.99K
Profits Per Employee: -$197.90K; -$46.47K
Employee Count: 420; 193

Income statement (TTM)Industry

Revenue: $127.27M; $108.17M
Gross Profit: $74.61M; $62.29M
Operating Income: -$92.58M; -$3.72M
Net Income: -$83.12M; -$6.19M
EBITDA: -$92.58M; -$1.98M
EPS (Diluted): -$1.84; -$0.11

Balance sheetIndustry

Cash & Short-Term Investments: $240.20M; $38.97M
Net Cash (Debt): $240.20M; $3.95M
Net Cash Per Share: $4.42; $0.26
Equity (Book Value): $401.38M; $63.80M
Book Value Per Share: $7.38; $3.26
Tangible Book Value: $401.38M; $11.61M
Working Capital: $260.11M; $57.32M

Cash flow (TTM)Industry

Operating Cash Flow: -$59.37M; -$483.87K
Capital Expenditures: -$6.59M; -$3.94M
Free Cash Flow: -$65.96M; -$238.00K
FCF Per Share: -$1.21; -$0.00

Dividends and yieldsIndustry

Earnings Yield: -9.31%; -4.76%
FCF Yield: -7.39%; 0.28%

Scores and fair valueIndustry

Altman Z-Score: 11.55; 2.47
Piotroski F-Score: 6; 5

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	BBNX	S&P 500	Difference
1 month	-7.2%	-3.0%	−4.1 pts
3 months	-9.2%	-2.8%	−6.4 pts
Year to date	-46.1%	+11.5%	−57.6 pts
1 year	-37.4%	+13.5%	−50.9 pts

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

5M BBNX shares were sold short on Oct 30, 2026, down 28.0% from the previous report, or 10.10% of the shares available to trade. At recent volumes it would take 3.9 days to buy them back. Over the last 20 sessions, 56.0% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	4,980,771	-28.0%	1,265,283	3.9
Oct 15, 2026	6,917,021	+14.4%	936,755	7.4
Sep 30, 2026	6,046,389	-43.1%	1,859,712	3.3
Sep 15, 2026	10,617,768	+12.9%	1,070,962	9.9
Aug 31, 2026	9,400,691	+25.4%	1,043,173	9.0
Aug 14, 2026	7,494,706	-1.4%	1,369,658	5.5
Jul 31, 2026	7,604,900	+15.1%	1,263,408	6.0
Jul 15, 2026	6,609,679	-3.1%	948,708	7.0
Jun 30, 2026	6,819,825	+45.9%	1,155,462	5.9
Jun 15, 2026	4,674,427	-10.1%	1,042,160	4.5
May 29, 2026	5,199,951	-8.6%	721,094	7.2
May 15, 2026	5,688,126	-8.2%	624,527	9.1

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Beta Bionics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BBNX.

Compare: BBNX vs KMTS · BBNX vs PDEX · BBNX vs RCEL · BBNX vs INFU · BBNX vs ANIK

Revenue growth43.7% · median 13.3%

Gross margin58.6% · median 57.6%

Operating margin-72.7% · median -2.1%

Net margin-65.3% · median -1.4%

Company	Revenue	Growth
INFU	$144.44M	+2.4%
BBNX	$127.27M	+43.7%
ANIK	$123.43M	+9.4%
KMTS	$106.73M	+60.7%
RCEL	$84.68M	+17.0%
PDEX	$79.58M	+13.3%

Company

Next earnings (est.): Feb 16, 2027, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 420
Held by institutions: 88.2%
Auditor: Ernst & Young LLP
SEC CIK: 1674632

Advertisement
300 × 250

See a number that looks wrong?